Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6817-6826

  Valerie, Nicholas C K ^a   Casarez, Eli V ^a   DaSilva, John O ^a   Dunlap Brown, Marya E ^a   Parsons, Sarah J ^a,b   Amorino, George P ^a   Dziegielewski, Jaroslaw ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MECLINERTANT; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL CLONING; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIZATION; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZOLES; QUINOLINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; RECEPTORS, NEUROTENSIN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80155131131     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1646     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Sandler HM, Mirhadi AJ. Radical radiotherapy for prostate cancer is the "only way to go." Oncology (Williston Park, N.Y.) 2009;23: 840-3.
4. Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009;45:2825-34.
5. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105. (Pubitemid 34787842)
6. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-48.
7. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14:287-300. (Pubitemid 40221058)
8. di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-61. (Pubitemid 26234584)
9. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001;12:S135-40.
10. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489-95. (Pubitemid 39006573)
11. Deeble PD, Cox ME, Frierson HF, Sikes RA, Palmer JB, Davidson RJ, et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67:3663-72. (Pubitemid 46762151)
12. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973;248: 6854-61.
13. Evers BM. Neurotensin and growth of normal and neoplastic tissues. Peptides 2006;27:2424-33.
14. Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 2006;27:2445-60. (Pubitemid 44402788)
15. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 2007;26:745-56. (Pubitemid 46204253)
16. Souazé F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 2006;66:6243-9.
17. Dupouy S, Viardot-Foucault V, Alifano M, Souazé F, Plu-Bureau G, Chaouat M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One 2009;4:e4223.
18. Gui X, Guzman G, Dobner PR, Kadkol SS. Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides 2008;29:1609-15.
19. Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, Chazono H, et al. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer 2008;123: 1816-23.
20. Elek J, Pinzon W, Park KH, Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res 2000;20:53-8. (Pubitemid 30189733)
21. Swift SL, Burns JE, Maitland NJ. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res 2010;70:347-56.
22. Hassan S, Dobner PR, Carraway RE. Involvement of MAP-kinase, PI3- kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regul Pept 2004;120:155-66. (Pubitemid 38726205)
23. Labbé-Jullié C, Botto JM, Mas MV, Chabry J, Mazella J, Vincent JP, et al. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol 1995;47:1050-6.
24. Oury-Donat F, Thurneyssen O, Gonalons N, Forgez P, Gully D, Le Fur G, et al. Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells. Br J Pharmacol 1995;116:1899-905.
25. Rostene W, Azzi M, Boudin H, Lepee I, Souaze F, Mendez-Ubach M, et al. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Ann N Y Acad Sci 1997;814:125-41.
26. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, et al. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg Oncol 1996;5:245-51. (Pubitemid 27153628)
27. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, et al. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 1997;79:1787-93. (Pubitemid 27176362)
28. Herzig MC, Chapman WG, Sheridan A, Rake JB, Woynarowski JM. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692. Anticancer Res 1999;19:213-9. (Pubitemid 29168240)
29. Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997; 31:183-92. (Pubitemid 27225203)
30. Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 2001;22:109-15. (Pubitemid 32146689)
31. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12. (Pubitemid 24168617)
32. Dziegielewski J, Baulch JE, Goetz W, Coleman MC, Spitz DR, Murley JS, et al. WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability. Free Radic Biol Med 2008;45:1674-81.
33. Dal Farra C, Sarret P, Navarro V, Botto JM, Mazella J, Vincent JP. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int J Cancer 2001;92:503-9. (Pubitemid 32319423)
34. Freytag SO, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A, et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002;54:873-85.
35. Jenkins DE, Yu S-F, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003;20:745-56. (Pubitemid 38019276)
36. Dittmann K, Mayer C, Kehlbach R, Rothmund M-C, Peter Rodemann H. Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol 2009;92:379-82.
37. Sturla L-M, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, Schmidt-Ullrichr RK. Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J Biol Chem 2005;280: 14597-604. (Pubitemid 40562804)
38. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-8. (Pubitemid 34832256)
39. Song Q, Lees-Miller SP, Kumar S, Zhang Z, Chan DW, Smith GC, et al. DNA-dependent protein kinase catalytic subunit: a target for an ICElike protease in apoptosis. EMBO J 1996;15:3238-46. (Pubitemid 26231929)
40. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008;14:5142-9.
41. Liu F, Yang P, Baez M, Ni B. Neurotensin negatively modulates Akt activity in neurotensin receptor-1-transfected AV12 cells. J Cell Biochem 2004;92:603-11.
42. Huamani J, Willey C, Thotala D, Niermann KJ, Reyzer M, Leavitt L, et al. Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models. Int J Radiat Oncol Biol Phys 2008;71: 237-46.
43. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302-9. (Pubitemid 29301684)
44. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A 1993;90:65-9. (Pubitemid 23010250)
45. Martin S, Vincent J-P, Mazella J. Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. J Neurosci 2003;23:1198-205. (Pubitemid 36258899)
46. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, Gliemann J, et al. Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J 1999;18:595-604. (Pubitemid 29057244)
47. Linard C, Marquette C, Strup C, Aigueperse J, Mathe D. Involvement of primary afferent nerves after abdominal irradiation: consequences on ileal contractile activity and inflammatory mediator release in the rat. Dig Dis Sci 2003;48:688-97. (Pubitemid 36390669)
48. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009;21:185-93.
49. Brazil DP, Yang Z-Z, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29:233-42. (Pubitemid 38591317)
50. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs 2007;18:861-74. (Pubitemid 47220704)
51. Somaï S, Gompel A, Rostène W, Forgez P. Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophys Res Commun 2002;295:482-8. (Pubitemid 34785860)